Benzinga | Nov 30, 2021 04:47PM EST

B. Riley Securities Maintains Buy on BioVie, Lowers Price Target to $27

B. Riley Securities analyst Mayank Mamtani maintains BioVie (NASDAQ:BIVI) with a Buy and lowers the price target from $50 to $27.